COMP <GO>

HRTX vs PLRX // FORWARD P/E MULTIPLE

Heron Therapeutics Inc. (NASDAQ) VS. Pliant Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: HRTX 1 — PLRX 1

■ METRIC PARITY

LAST: $0.30 (+6.27%) • MKT CAP: $52.7M

forward-pe

—

LAST: $0.84 (-2.29%) • MKT CAP: $53.2M

forward-pe

—

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HRTX VS. PLRX) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	HRTX	PLRX	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	73.30%	—	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	-35.00%	-35.00%	0.00	TIE	/roic <GO>
EV/EBITDA & P/E Valuation	—	—	—	TIE	/valuation <GO>
Free Cash Flow Yield	—	—	—	TIE	/fcf-yield <GO>
Operating Margin	-1.60%	—	—	TIE	/operating-margins <GO>
Net Profit Margin	-12.90%	—	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	—	—	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity	—	—	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	2/9	2/9	0.00	TIE	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	37.6	35.3	+2.30	HRTX	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple ACTIVE	—	—	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$52.7M	$53.2M	-$462.7K	PLRX	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	HRTX REV	PLRX REV	HRTX GROSS %	PLRX GROSS %	HRTX FCF	PLRX FCF
FY 2025	$154.9M	$437.8M	73.3%	—	-$27.9M	-$128.7M
FY 2024	$144.3M	$639.4M	73.2%	—	-$24.2M	-$159.4M
FY 2023	$309.7M	$1.6M	—	—	-$58.8M	-$116.4M

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

HRTX // BETA —

PLRX // BETA —